Key features and details
- Expression system: HEK 293 cells
- Purity: >= 95% SDS-PAGE
- Endotoxin level: < 0.100 Eu/µg
- Active: Yes
- Suitable for: Functional Studies, SDS-PAGE
Product nameRecombinant human FGF21 + IgG1 fusion protein (Fc Chimera Active)
Biological activityActivates ERK and FRS2alpha phosphorylation in bKlotho expressing cells.
Purity>= 95 % SDS-PAGE.
ab108556 is 0.2 µm filtered.
Endotoxin level< 0.100 Eu/µg
Expression systemHEK 293 cells
Protein lengthFull length protein
Predicted molecular weight50 kDa including tags
Additional sequence informationHuman FGF21 (aa 1-209) is fused at the C-terminus to the Fc portion of human IgG1.
DescriptionRecombinant human FGF21 + IgG1 protein (Fc Chimera Active)
Our Abpromise guarantee covers the use of ab108556 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Additional notesWorking aliquots are stable for up to 3 months when stored at -20°C.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Cellular localizationFGF21: Secreted. IgG1: Secreted. Cell membrane; Single-pass membrane protein
ERK and FRS2alpha phosphorylation induced by FGF21 in bKlotho expressing cells.
bKlotho expressing cells were serum starved for 16hr and then stimulated with hFGF21-His (competitor), ab108556 (FGF 21-Fc), mCD137-Fc (Fc control) and FGF-b (positive control) for 10 minutes, respectively.
Antibodies against pFRS2alpha, pERK1/2 & total ERK1/2 were used for immunoblotting.
Lane 1: 1 μg/ml hFGF21-His (competitor)
Lane 2: 2.2 μg/ml ab108556 (hFGF21-Fc)
Lane 3: 2.2 μg/ml mCD137-Fc
Lane 4: 100 ng/μl FGF-b
Lane 5: control (non-treated)
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab108556 has not yet been referenced specifically in any publications.